🇺🇸 FDA
Patent

US 12286406

Inhibitors of receptor interacting protein kinase I for the treatment of disease

granted A61KA61K31/40A61K31/4015

Quick answer

US patent 12286406 (Inhibitors of receptor interacting protein kinase I for the treatment of disease) held by The Board of Regents of the University of Texas System expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/40, A61K31/4015, A61K31/415, A61K31/4155